Stockscreener 앱 받기
19.83
1.05%
-0.21
시간 외 거래:
19.83
전일 마감가:
$20.04
열려 있는:
$19.9
하루 거래량:
2.69M
Relative Volume:
2.92
시가총액:
$1.40B
수익:
$80.89M
순이익/손실:
$-144.73M
주가수익비율:
-6.6768
EPS:
-2.97
순현금흐름:
$-83.87M
1주 성능:
-2.17%
1개월 성능:
-12.41%
6개월 성능:
-5.44%
1년 성능:
+101.73%
1일 변동 폭
$19.66
$20.61
1주일 범위
$19.38
$21.67
52주 변동 폭
$7.65
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.83 | 1.40B | 80.89M | -144.73M | -83.87M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Jane Street Group LLC Has $3.54 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
State Street Corp Sells 337,262 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Nurix's BTK Degrader NX-5948 Earns FDA Fast Track Status for Rare Blood Cancer Treatment - StockTitan
State Street Corp Cuts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics' SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com
Lord Abbett & CO. LLC Purchases Shares of 350,640 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.35 - MarketBeat
When (NRIX) Moves Investors should Listen - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company - Defense World
BTIG Initiates Coverage of Nurix Therapeutics (NRIX) with Buy Recommendation - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Fmr LLC - MarketBeat
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given New $35.00 Price Target at HC Wainwright - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at BTIG Research - MarketBeat
Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports Promising Trial Results for NX-5948 - TipRanks
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com India
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - The Manila Times
Nurix Therapeutics Presents New Positive Data from Phase - GlobeNewswire
Charles Schwab Investment Management Inc. Sells 111,684 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 8.3%Here's What Happened - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by BMO Capital Markets - MarketBeat
Polar Asset Management Partners Inc. Purchases Shares of 27,000 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Decoding 9 Analyst Evaluations For Nurix Therapeutics - Inkl
Where are the Opportunities in (NRIX) - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Redmile Group LLC - MarketBeat
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds - Insider Monkey
Patient Square Capital LP Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Parkman Healthcare Partners LLC Decreases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Cinctive Capital Management LP Buys Shares of 105,228 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics chief legal officer sells $125,155 in stock By Investing.com - Investing.com Canada
Nurix Therapeutics chief legal officer sells $125,155 in stock - Investing.com
Nurix Therapeutics Announces Webcast To Review New Data - GlobeNewswire
Nurix Therapeutics Announces Webcast to Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented At the American Society of Hematology Annual Meeting - Marketscreener.com
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting - The Manila Times
Fred Alger Management LLC Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wasatch Advisors LP Has $15.92 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
23,578 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by Dynamic Technology Lab Private Ltd - MarketBeat
Vestal Point Capital LP Sells 75,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Massachusetts Financial Services Co. MA Sells 28,756 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics CEO to Present at Piper Sandler Healthcare Conference | NRIX Stock News - StockTitan
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
(NRIX) Proactive Strategies - Stock Traders Daily
GSA Capital Partners LLP Sells 15,134 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
누릭스 테라퓨틱스 주식 (NRIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Dec 02 '24 |
Sale |
21.73 |
5,760 |
125,155 |
28,084 |
2.88%
2.65%
자본화:
|
볼륨(24시간):